Natco Pharma said it plans to utilize the cash flows generated by the launch of generic versions of Israel-based Teva’s top selling multiple sclerosis Copaxone 20 mg/ml and 40 mg/ml by its partner Mylan in US towards strengthening balance sheet and investing on business expansion.
While the Sorafenib drug is not a big opportunity for Natco, approval from Kothur plant is a big positive, says Praful Bohra of Religare Capital Markets.
In the last five months, plants of nine Indian pharmaceutical companies - Cipla, Dr Reddy‘s, Sun Pharma, Cadila, Lupin and Natco Pharma.- have come under the US Food and Drug Administration (FDA) scanner.
Sumit Singhania of Nirmal Bang says that the observations are minor and can be resolved easily.
Jaideep Gogtay, Clinical Head at Cipla pointed out that in India the cost of treatment of Hepatitis C ranges between Rs 75,000 to Rs 1.5 lakh per patient, depending on the type of virus and the intensity.
Bhaskar Narayana, Finance Director & CFO, Natco Pharma is confident of maintaining the current growth rate in terms of margins going forward.
Hyderabad-based Natco Pharma Limited, on December 21, received the approval from Food & Drug Administration (FDA) for marketing the prescription version of Lanzoprazole, CFO of the company Bhaskar Narayana told CNBC-TV18 in an interview.
In an interview with CNBC-TV18, Bhaskar Narayana, finance director & CFO of Natco Pharma spoke about the judgment where the company is granted compulsory license to manufacture one of the Bayer’s products. He also talks about the market size of the drug and the amount of royalty to be paid.
In an interview to CNBC-TV18, Bhaskar Narayana, chief financial officer of Natco Pharma says, FY13 should see atleast one abbreviated new drug application (ANDA) coming through. “FY13 would be a very exciting year for the company because it should result in good boost to the revenues,” he adds.
Some agencies have been reporting that Natco Pharma’s fund raising plan might be expedited and take place in the next one or two months. Finance director and chief financial officer Bhaskar Narayana told CNBC-TV18 that the Rs 100 crore qualified institutional placement (QIP) would result in 7-8% dilution.
In an interview with CNBC-TV18, Bhaskar Narayana, Finance Director & CFO of Natco Pharma talks about the pact with the Swiss based company and its impact on the company’s revenues going forward.
In an interview on CNBC-TV18, Bhaskar Narayana, finance director and chief financial officer at Natco Pharma said that synergies with the SaveMart Pharmacy exist no longer.
In an interview with CNBC-TV18, Bhaskar Narayana, Finance Director & CFO, Natco Pharma said," In a patently challenged issue, the innovator is bound to protect his rights and this can be done only through the mechanism of suing.There is nothing extra-ordinary about it."
In an interview with CNBC-TV18, Bhaskar Narayana, Finance Director and CFO, Natco Pharma, speaks about the results and gives his outlook going forward.
In an interview with CNBC-TV18, Bhaskar Narayana, Finance Director & CFO, Natco Pharma gave his perspective on the tie-up with Alvogen and the first-to-file opportunity for Tamiflu.
Hyderabad-based Natco Pharma has sought permission from drug major Pfizer to sell discounted copies of its HIV drug. In an interview with CNBC-TV18, Bhaskar Narayana, Finance Director & CFO, Natco Pharma threw light on the development and spoke on the company's business plans going forward.